Blog Read the latest perspectives from our team of subject matter experts and others How Incyte Is Advancing Clinical Trial DiversityDiversity in clinical trials is more than just a regulatory requirement—it’s a critical component of equitable healthcare. Ensuring that trial participants reflect the real-world patient population leads to more… Continue reading → Read the article Post Topics:Artificial Intelligence Commercialization Drug Development Global Impact HCP Volunteers KOL Engagement Patient Representation Provider Data Research Post Industries:Commercialization Global Impact Health Plans & Digital Health Pharmaceutical & Biotechnology Provider Data Research KOL EngagementRedefining Medical Affairs Strategy with DataAs the role of Medical Affairs continues to evolve, data plays an increasingly critical role in shaping key opinion leader (KOL) engagement strategies, identifying care gaps, and ensuring equitable… Continue reading → Read the articleno Artificial IntelligenceKOL EngagementProvider DataA Holistic Approach to Measuring ImpactMedical Affairs plays an essential role in evidence-based medicine, disease education, and driving better outcomes. Their knowledge is crucial as medications become more specialized and complex. They enable healthcare… Continue reading → Read the articleno Artificial IntelligenceCommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchTrials, Data, Diversity – H1’s Top 5 Diagnoses (Predictions) for Biotech and Pharma in 2024How will AI impact clinical trials? Will FDA legislation improve diversity? What platforms will key opinion leaders adopt? Every year, we take a look at annual predictions to help life… Continue reading → Read the articleno KOL EngagementCompliant Science: The Critical Role of Compliance for Medical AffairsIn medical affairs, building and managing relationships with key opinion leaders (KOLs) is a critical component of successful product launches and long-term growth. But in today’s highly regulated environment,… Continue reading → Read the articleno KOL EngagementBoost HCP Access with a Unified Healthcare Data PlatformIn an August 2022 market research study conducted by H1 and the Medical Science Liaison Society (MSLS), more than 600 MSLs surveyed weighed in on their experiences and preferences… Continue reading → Read the articleno KOL EngagementKOL to Go? The Modern MSL & Mobile AppsAs the pharmaceutical industry becomes increasingly competitive, speed and efficiency are crucial for getting drugs to market faster. This is where mobile apps come in. And at the heart of… Continue reading → Read the articleno KOL EngagementFrom Academia to Patients: The Evolution of MSL TerritoriesAs the role of the Medical Science Liaison (MSL) has evolved from academic rigor to understanding disease trends, a key component of MSL territory planning is collaboration with Key… Continue reading → Read the articleno KOL EngagementNavigating HCP Digital Engagement: Best PracticesAs medical education evolves, the need for effective digital engagement strategies is also growing. In order to ensure that healthcare professionals (HCPs) have access to the most up-to-date information… Continue reading → Read the articleno Drug DevelopmentKOL EngagementPatient RepresentationBuilding an Exclusive Strategy with Inclusive HCPsAs healthcare providers (HCPs) are increasingly relying on evidence-based data and clinical guidelines, life science organizations must shift their focus to enabling HCPs in the effective adoption of these medicines.… Continue reading → Read the articleno KOL EngagementLet’s Get Personal: Four Benefits to Omnichannel StrategiesWith the proliferation of digital media, marketing in the healthcare industry has shifted from traditional tactics to an omnichannel approach. Omnichannel engagement for physician marketing is a powerful tool… Continue reading → Read the articleno KOL EngagementNurses: The Unsung Heroes in Pharma and Biotech for Health Equity and Medication AdherenceHealthcare providers are often the first line of defense in ensuring that people receive the medical treatment they need. But nurses are often overlooked as a solution to addressing health… Continue reading → Read the articleno KOL EngagementPatient RepresentationFour Ideas for Pharma to Maximize the Influence of Digital Opinion Leaders in MedicinePharmaceutical companies have long recognized the importance of engaging key opinion leaders (KOLs) to gain insight and support for clinical research, drug development, and medical education. With the rise… Continue reading → Read the articleno KOL EngagementThree Ways Field Medical Teams Can Close Care Gaps and Increase Scientific Share of VoiceAs the primary interface between healthcare providers (HCPs) and pharmaceutical companies, medical science liaisons (MSLs) have a unique opportunity to engage with HCPs in clinical discussions and bridge care gaps… Continue reading → Read the articleno CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchH1 Honored with a Spot on Y Combinator’s 2023 Best Companies List and Slice of Healthcare’s Inaugural Digital Health Leaders ListH1, the connecting force for global healthcare provider, clinical, science, and research information, today announced that it has been recognized in two prestigious annual lists: Y Combinator’s 2023 Best Companies… Continue reading → Read the articleno CommercializationKOL EngagementMedical Public Awareness Campaigns—Examples and EffectivenessMedical public awareness campaigns are designed to distribute important healthcare messages to large populations. With over seven billion people in the world, it is necessary to find ways to share… Continue reading → Read the article KOL EngagementTis the Season…for Conference PlanningAs we come out of the holidays , in the United States, some of the greatest minds in medicine and healthcare are gathered this week at the JP Morgan Healthcare… Continue reading → Read the articleno CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchNew Look, Same Commitment!I’m excited to officially unveil the new branding and website our team has been working on for several months. This new branding comes with much thought and consideration, and reflects… Continue reading → Read the articleno Artificial IntelligenceKOL EngagementAI and the MSL Evolution: What Time Has Taught UsI recently had the chance to deliver the keynote address at the 2022 MSL Society Conference in Las Vegas. It’s been a transformative year for pharma and life sciences, specifically… Continue reading → Read the article CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchTimmy Awards Announces H1 as 2022 Tech for Good FinalistThe 8th Annual Timmy Awards run by Tech in Motion celebrates leaders in tech, recognizing the top workplaces for tech professionals across North America. We are thrilled to announce that H1 is… Continue reading → Read the article KOL EngagementGoing with the Digital FlowEven now: two and a half years later, the COVID-19 pandemic continues to have a substantial impact on the activities of Medical Science Liaisons (MSLs), including access to Key… Continue reading → Read the article Drug DevelopmentKOL EngagementPatient RepresentationA New Reflection on Pharma, Research, and Patient CarePharma has long existed in elevated, prestigious academic institutions: ivory towers of reputable and revered centers of excellence famous for disseminating the latest in clinical research and medical breakthroughs.… Continue reading → Read the article Drug DevelopmentKOL EngagementH1 Announces Partnership with Society for Clinical Research SitesThe Society for Clinical Research Sites (SCRS) announced today that H1, a pioneer in creating connected ecosystems where data, people, research, and clinical trial intelligence come together to drive the… Continue reading → Read the article CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchThe Evolution of H1’s Core ValuesI remember it clearly. Me, Ian – our co-founder and a handful of brave individuals who would become the first H1 employees, sitting around a table writing down the values… Continue reading → Read the article KOL EngagementA Case Study on Global KOL EngagementIn a recent issue of Nature that traced the origins of key opinion leaders in pharma back to a Pfizer launch in the mid-1950s, the article tracked the evolution and… Continue reading → Read the article KOL EngagementReuters Pharma and MAPS 2022 Event Wrap-UpEvents are back in person and there’s a buzz in the air. Stacey Rivkin, H1’s VP of Client Strategy & Solutions just got back from the 2022 Medical Affairs… Continue reading → Read the article CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchH1 Recognized as One of Forbes’ Best Startup Employers 2022H1, which provides the largest global healthcare professional data ecosystem to enable life sciences, academic medical institutions, health systems, and payers, today announced it has been included on Forbes’… Continue reading → Read the article CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchH1 Named to NYC Digital Health 100 by NYCHBLH1, which provides the largest global healthcare platform that connects healthcare professionals, today announced that New York City Health Business Leaders (NYCHBL), the organization that serves as the gateway to… Continue reading → Read the article CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchH1 Wraps Up 2021 with Gratitude2021 was a year of enormous change around the world, as we learn to live and work in new ways. For H1, it was also a year of enormous growth,… Continue reading → Read the article CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchCo-Founder and CEO of H1 Named to Forbes 30 Under 30H1 announced today that its CEO and Co-Founder Ariel Katz was named to the prestigious Forbes 30 under 30 list. Ariel started his first company in college, ResearchConnection, to help… Continue reading → Read the article CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchZiad Ismail Joins H1 During Period of High GrowthH1, which provides the largest global healthcare network that connects healthcare professionals, announced today that it has added Ziad Ismail to the management team as Chief Operating Officer. Ziad… Continue reading → Read the article CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchH1 Raises Series CToday we announced our Series C of $100 million led by Altimeter and participation from new investors including Goldman Sachs Asset Management and Flex Capital. It also includes the support… Continue reading → Read the article KOL EngagementHow Physicians Are Compensated by Life Sciences CompaniesIt’s no secret that compensation for physicians consulting at pharmaceutical, device and life sciences firms is often much higher than what’s on the table at hospitals and university-affiliated medical centers.… Continue reading → Read the article CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchFormer Dropbox CIO Joins Board of Healthcare Data Startup H1Board member Sylvie Veilleux (Salesforce, Dropbox), CFO Karen Moran (Alteryx, Domo) and CDO Mayur Thakur (Goldman Sachs, Google) bring decades of experience and add bench strength as H1 expands.… Continue reading → Read the article KOL EngagementWhy Physicians May Want to Become Key Opinion LeadersDuring drug development, life science companies often turn to healthcare professionals (HCPs) for input, advice and expertise. These HCPs advising companies are generally known as Key Opinion Leaders (KOLs), thought… Continue reading → Read the article KOL EngagementEducating Physicians to Improve the Patient Diagnostic JourneyThe best diagnostic journey for a patient is the shortest. The less time is lost between a patient seeing a healthcare provider for the first time for their symptoms… Continue reading → Read the articleno KOL EngagementDr. Sekar Kathiresan’s Impact on CardiologyScholarly Influence Publications Dr. Kathiresan is a cardiologist and the CEO of Verve Therapeutics, a company that works on gene editing medicine for cardiovascular disease. Additionally, he is… Continue reading → Read the article KOL EngagementThe Term KOL: Keep It or Ditch It?Listening to webinars and reading reports about the latest trends and developments in medical affairs is one of the things we do incessantly at H1 – after all we need… Continue reading → Read the article KOL EngagementThe Power of Micro-Influencers in HealthcareHow can we break through the noise to reach healthcare providers and key opinion leaders with important information? Consistently engaging external experts has always been one of the main… Continue reading → Read the article KOL EngagementDr. Krishna Aragam’s Impact on CardiologyScholarly Influence Publications Dr. Aragam is a Rising Star and Preventive Cardiologist at Massachusetts General Hospital as well as an Instructor of Medicine at Harvard Medical School. According to… Continue reading → Read the article KOL EngagementHow to Engage the Payer CommunityEven before COVID threw the entire healthcare ecosystem into disarray, payers as well as the healthcare market in general faced significant cost pressure. Healthcare payers reacted with consolidation and vertical… Continue reading → Read the article KOL EngagementKey Opinion Leader: Dr. Naveed Sattar’s ImpactScholarly Influence Publications Dr. Naveed Sattar is a top healthcare professional specializing in Endocrinology, Diabetes & Metabolism, and Cardiovascular Disease. He is renowned for his work in diabetes.… Continue reading → Read the article KOL EngagementKey Opinion Leader: Dr. Hugh Sampson’s ImpactPublications Scholarly Influence Dr. Hugh Sampson is an esteemed healthcare professional with a specialty in pediatric allergy and immunology. He is the Kurt Hirschhorn Professor of Pediatrics at the… Continue reading → Read the article Drug DevelopmentKOL Engagement9 Ways Medical Affairs Can Use Claims and Referral DataIn a recent interview an experienced medical affairs professional reminisced about the days when key opinion leader selection was a difficult and time consuming activity, which often relied on established… Continue reading → Read the article KOL EngagementProvider DataConnecting the Dots between Patients, Physicians and PayorsSuccessful engagement of external experts ranks very high on the list of challenges medical affairs professionals face. No surprise here, building relationships that support long-term engagement is hard under… Continue reading → Read the article KOL EngagementKey Opinion Leader: Dr. Morie Gertz’s Impact on Hematology & OncologyPublications Scholarly Influence Dr. Morie Gertz is a leading healthcare professional whose specialty is oncology and hematology. Dr. Gertz works at the Mayo Clinic in Minnesota and is the… Continue reading → Read the article KOL EngagementHelpful Hints for MSLsBeginning a new job is exciting, even though new jobs often come with new obstacles and potential challenges. Through the duration of the application process, the prospect of being a… Continue reading → Read the article CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchH1 Closes $58 Million Series B FundingToday, H1 announced a $58 million Series B round of funding to continue working towards our mission of creating a healthier future by connecting parties in the healthcare ecosystem.… Continue reading → Read the article KOL EngagementComplying with MSL RegulationsMedical Science Liaisons (MSLs) are members of the Medical Affairs departments in pharmaceutical companies and have a wide range of responsibilities. An important part of the MSL role is… Continue reading → Read the article KOL EngagementMSL Conduct Dos and Don’tsMedical Science Liaisons (MSLs) are in the field (almost) every day and so are their field-based commercial colleagues, specifically sales representatives. Although they interact with the same people, healthcare… Continue reading → Read the article KOL EngagementPayer Mix: Understanding How Patients Receive Care and Who Pays for itTo find out which healthcare providers (HCPs) are actively treating patients in a therapeutic area, you’ll want access to more than just publication information. To really dig in, you… Continue reading → Read the article KOL EngagementAnnouncing A New Way to Identify KOLs with Claims DataPublications can only get you so far. If your medical affairs team really wants to know who’s actively treating patients in a therapeutic area, you need access to claims data.… Continue reading → Read the article KOL EngagementThe Importance of an Integrated KOL Engagement StrategyBuilding long-term, mutually beneficial relationships with external stakeholders such as physicians, key opinion leaders (KOLs) and other experts is the ultimate goal of medical affairs, specifically medical science liaisons (MSLs).… Continue reading → Read the article KOL Engagement5 Daily Challenges of MSLsThe job of an MSL is not for the faint of heart: an exciting job for scientists or medical doctors, being an MSL is not without a set of challenges.… Continue reading → Read the article Drug DevelopmentKOL EngagementThe Future of Medical AffairsIt is not the first time we say this: healthcare is rapidly changing and is driven by several different factors, chief among them our ability to create ever-increasing amounts… Continue reading → Read the article KOL EngagementHealth Outcomes Liaison – Managing Relationships with PayorsThe job of a Medical Science Liaison (MSL) comes with an amazing variety of responsibilities. In addition, to building and maintaining relationships with key opinion leaders, MSLs are increasingly tasked… Continue reading → Read the article Drug DevelopmentKOL EngagementClinical Trial Enrollment ChallengesWe talk a lot about Medical Science Liaisons (MSLs) and Key Opinion Leaders (KOLs) and their roles and responsibilities. We also dedicated a blog to the emerging role of… Continue reading → Read the article KOL EngagementThe Typical Medical Science LiaisonWe have been writing about Medical Science Liaisons, their jobs, responsibilities, typical job descriptions, scientific background, challenges – regulatory and otherwise – and rewards, about the key opinion leaders (KOLs)… Continue reading → Read the article Artificial IntelligenceKOL Engagement5 Ways Artificial Intelligence Will Benefit Medical Science LiaisonsBy now, pretty much everybody agrees that artificial intelligence (AI) will change all of our lives forever. From transportation to quality control, from education to medicine, from entertainment to manufacturing,… Continue reading → Read the article KOL EngagementWhich Types of Skills Are Most Valuable to MSLsMedical Science Liaisons (MSL) are science subject matter experts first and foremost. They educate physicians about their drugs, the underlying science, and details of clinical studies. In addition, they… Continue reading → Read the article KOL EngagementThe Importance of KOLsMuch is written about the importance of key opinion leaders (KOLs) for the pharmaceutical industry. These independent medical and scientific experts advise pharma companies on a broad range of activities,… Continue reading → Read the article KOL EngagementKOL Presentations Go DigitalWe live in an increasingly digital world and key opinion leaders (KOLs) are no exception. Though face-to-face meetings and presentations are still the preferred way for KOLs to interact with… Continue reading → Read the article Drug DevelopmentKOL EngagementThe Roles of KOLs in the Drug Development ProcessKey opinion leaders (KOLs) play an important role throughout the entire drug development and approval process. Most companies work with KOLs during Phases IIIa and IIIb as well as during… Continue reading → Read the article KOL EngagementOpinion Leader Identification: Big Data to KOL Short ListFor a pharmaceutical company, the decision to work with a certain key opinion leader (KOL) is very important. Engaging the right KOL is critical in establishing credibility among physicians… Continue reading → Read the article KOL EngagementThe Science of Building and Maintaining a KOL DatabaseA lot has been written about KOLs and the value they can bring not only to drug development and commercialization in the pharmaceutical industry but also to companies developing medical… Continue reading → Read the article KOL EngagementThe Challenge of Performance Review for Medical Science LiaisonsThe daily responsibilities of a Medical Science Liaison (MSL) are varied and broad but a common denominator is their central role in interacting with, informing, and educating stakeholders in… Continue reading → Read the article
